



DRUG PRIOR AUTHORIZATION COMMITTEE AGENDA

Date:
March 17, 2022

Time:
10:00am – 3:00pm (CST)

Location:
Department of Natural Resources
See Additional Details Below

DPAC Meeting Additional Details

The March 17th DPAC meeting will have both in-person and virtual attendance options. The meeting will be hosted at the Department of Natural Resources, Lacharette/Nightingale Rooms located at 1101 Riverside Dr, Jefferson City, MO 65101. Due to strict capacity limits, public attendance will be based on a first come/first serve sign-up, with a limit of **1 individual per organization**.

Those unable to join in-person may listen in/provide public comment via Webex. Individuals wishing to attend in-person must contact **Carmen Burton** at Carmen.M.Burton@dss.mo.gov or call (573) 751-6961.

[Join Webex Meeting](#)

Meeting number (access code): 2458 000 9614
Meeting password: qwYq4ayyJ63

Join from a Video System/Application
Dial [24580009614@stateofmo.webex.com](tel:24580009614)
Or dial 173.243.2.68 and enter the meeting number

Join from a Mobile Device (attendees only)
[1-650-479-3207](tel:1-650-479-3207) Call-in toll number (US/Canada)

[* Click HERE for Meeting Documents *](#)

Opening Statements/Updates

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/Budget Update	Elizabeth Short
10:25 – 10:35	Review of Prior Authorization Meeting and Public Hearing	Josh Moore

Old Business

10:35 – 10:45	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
---------------	--	------------

New Business

10:45 – 11:00	Proposed Actions - New Drug/Product Review (See Website and Attached Summary)	Olivia Rush
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. PDL Agents	
	iv. Prior Authorization	

Clinical and Fiscal Edit Review

11:00 – 11:45	<u>Existing Criteria</u>	Josh Moore
	i. Imcivree	
	ii. Megestrol	
	iii. Nulibry	
	iv. Oxervate	
	v. Oxlumo	

- vi. Spravato
- vii. Zokinvy
- viii. Zulresso

New Criteria or Revision of Existing Criteria

- i. Acne or Rosacea, Select Topical Agents
- ii. C5 Complement Inhibitors
- iii. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
- iv. Fabry Disease
- v. Givlaari
- vi. Isturisa
- vii. Scenesse
- viii. Sickle Cell Disease
- ix. Systemic Antifungals
- x. Tavneos
- xi. Voxzogo

Break

11:45 – 12:00 Lunch

Preferred Drug List Edit Review

12:00 – 2:00 Existing Criteria Josh Moore

- i. Actinic Keratosis Agents, Topical
- ii. Androgenic Agents
- iii. Antibiotics, Inhaled
- iv. Antifungals, Oral
- v. Antifungals, Topical
- vi. Antihistamines & Antihistamines/Decongestant Combinations, 2nd Generation
- vii. Antihistamines, Intranasal
- viii. Antivirals, Herpes Oral
- ix. Antivirals, Topical
- x. Benzoyl Peroxide/Antibiotic Combinations
- xi. Corticosteroids, Oral Inhaled
- xii. Corticosteroids, Topical
- xiii. Corticosteroids and Rhinitis Agents, Intranasal
- xiv. Cough/Cold Preparations
- xv. Epinephrine Agents, Self-Injectable
- xvi. Fluoroquinolones, Ophthalmic
- xvii. Fluoroquinolones, Otic
- xviii. Glaucoma Agents
- xix. Mast Cell Stabilizers, Ophthalmic
- xx. NSAIDs, Ophthalmic
- xxi. Psoriasis Agents, Oral
- xxii. Psoriasis Agents, Topical
- xxiii. Retinoids, Topical
- xxiv. Ulcerative Colitis Agents, Oral
- xxv. Ulcerative Colitis Agents, Rectal

New Criteria or Revision of Existing Criteria

- i. Beta Adrenergic Agents, Nebulized
- ii. Beta Adrenergic Agents, Short Acting
- iii. Leukotriene Receptor Modifiers

- iv. Anticholinergics, LABAs/ICS Combinations and PDE4 Inhibitors
- v. Anticholinergics, Long Acting Inhaled
- vi. Anticholinergics, Short Acting and Combinations Inhaled
- vii. Anticholinergics, LABA Combinations
- viii. Antihistamines, Ophthalmic
- ix. Antiparasitics, Topical
- x. Atopic Dermatitis Agents, Immunomodulators
- xi. Beta Adrenergic Agents, Long Acting
- xii. Corticosteroids, Ophthalmic Soft
- xiii. Hepatitis C Agents PDL Edit
- xiv. Pancreatic Enzymes
- xv. Respiratory Monoclonal Antibodies

Program Utilization Information – Conduent Update

2:00 – 2:30

Reports

Jennifer Colozza

- i. Call Center Statistics
- ii. New Drug Statistics
- iii. “Top 25” Drugs by Cost/Claims

Other Business/Closing Comments

2:30 – 2:50

Other Business

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, agenda may move more quickly.

Next Meeting: June 16, 2022

Meeting location and attendance options subject to change

MO HealthNet
615 Howerton Ct
2nd Floor, Conference Room 202
Jefferson City, MO 65109
Public attendance may be limited

Webex

Motion to Close: *I move that this meeting be closed, and that all records and votes pertaining to and/or resulting from this closed meeting be closed, under Section 610.021 Subsection (14),(5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.*